Introduction
Malignant neoplasms of the sinonasal tract are uncommon. These tumors are diverse and include a variety of histopathologies such as squamous cell carcinoma (SCC) and adenoid cystic carcinoma (ACC).
1 Human papillomavirus (HPV) related multiphenotypic sinonasal carcinoma (HMSC), also known as HPV-related carcinoma with adenoid cystic-like features, is a recently described neoplasm restricted to the sinonasal tract, with histological features of high-grade, solid-type ACC, with HPV positivity and paradoxically indolent behavior.
2-4
HMSC was provisionally included in the 2017 World Health Organization classification of head and neck tumors as a candidate to be a separate tumor entity, different from ACC and SCC. 5 In contrast to ACC, HMSC (1) 
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to demonstrate the MYB gene fusions, and (4) has a more indolent clinical behavior.
3,6
The largest case series of HMSC is described by Bishop et al, who first suggested that these tumors have a favorable outcome. Most reports published since this series have followed this trend. 
Case Report
A 65-year-old man was referred to the Department of Otolaryngology with unilateral nasal congestion and epistaxis. Anterior rhinoscopy revealed a large mass occupying the entire left nasal cavity. The tumor was biopsied and initially diagnosed as nonkeratinizing HPV-related SCC. The patient underwent an endoscopic-assisted medial maxillectomy, achieving a gross total resection with negative margins. Pathology revealed a basaloid tumor consisting of solid nests with multiple foci of cribriform architecture (►Fig. 1). There was no overt squamous differentiation identified within the tumor, but surface epithelial squamous dysplasia was present. HPV testing by real-time polymerase chain reaction (Roche cobas 4800 HR-HPV analysis, Roche, Basel, Switzerland) was positive for HPV-16 and was confirmed by HPV-16/18 RNA in situ hybridization (RNAscope ACD HR16/18, Advanced Cell Diagnostics Inc., Newark, California, United States), showing positive staining within the carcinoma (►Fig. 2), thus supporting the diagnosis of HMSC. Immunohistochemical staining showed diffuse positivity for p16. In addition, the carcinoma was positive for p63 and CK7 and showed focal positivity for S100, calponin, and smooth muscle actin (►Fig. 2).
Two months postoperatively, the patient underwent threedimensional proton therapy to the paranasal sinuses to a total dose of 66.6 Gy. Twenty-three months after the surgical resection, he developed enlarging pulmonary nodules that had histological features consistent with metastasis from the primary sinonasal tumor. He was treated with three cycles of chemotherapy (carboplatin/taxol), with initial partial response but subsequent progression. He was then treated with immunotherapy (pembrolizumab) for eight cycles, but it was discontinued because of evidence of progressive disease on the PET-CT (positron emission tomography-computed tomography). He remains on palliative chemotherapy (fluorouracil/ cetuximab).
Discussion
HMSC is a newly identified pathological entity that has been suggested to be indolent despite a high-grade appearance on histopathology. Given the limited number of reported cases, the clinical behavior and consensus treatment guidelines have not yet been established. However, in view of the typically indolent behavior, it has been suggested that surgery with close monitoring has resulted in a good prognosis. 1, 9 This management is in direct contrast with most sinonasal malignancies that are treated with adjuvant therapy. Our case, however, is one with early and progressive metastatic disease despite gross total resection and adjuvant radiation therapy, highlighting an aggressive subset of this disease and the need to properly stratify patients to determine the need for adjuvant radiation or chemoradiation therapy. Most HMSC cases reported have positive outcomes following surgical removal alone or accompanied by radiotherapy. In the limited cases that recur, the tumors are slow growing, with the timing of recurrence ranging widely: the earliest local recurrence previously reported occurred 23 months posttreatment, and the latest recurrence previously reported occurred after a 30-year disease-free interval.
1,3,4,6-11 Most previously reported recurrences responded well to treatment, achieving long disease-free intervals. Only two cases previously reported progressed to distal metastasis after 96 and 144 months following their initial treatment. 3 Our case differs from others reported in the literature due to the very early development of distal metastasis in less than 2 years following the initial treatment. Furthermore, our patient's recurrence progressed even after chemotherapy and immunotherapy. We were not able to find reports of another HMSC tumor with such aggressive behavior, leading us to speculate that there may be a relation between its odd clinical and molecular characteristics. In the past, HMSC cases have frequently carried the diagnosis of ACC. As previously mentioned, several characteristics differentiate HMSC from ACC. Yet, another important diagnostic entity in the differential is basaloid SCC. Morphologically, it is difficult to distinguish HMSC from ACC or basaloid SCC due to the presence of solid and cribriform architecture and highly cellular lesions composed of basaloid and ductal cells.
1 Immunohistochemistry can help distinguish HMSC from HPV-related basaloid SCC, as the latter lacks the myoepithelial cells (often positive for cytokeratin, S100, actin, calponin, and p63) that make up salivary gland neoplasms.
13
From a molecular standpoint, the case we report herein is unique due to its association with high-risk HPV type 16, which, to the best of our knowledge, has only been reported twice previously, and in neither of these reports were the clinical outcomes specifically highlighted. 3, 6 Most HPV-positive head and neck carcinomas arise from the oropharynx, with the sinonasal tract now recognized as another anatomic "hotspot" for HPV-related neoplasms. 
Conclusion
Here, we present an HPV16-associated case of HMSC with early and progressive metastatic disease. As more HMSC cases are identified, the clinical management of this entity may be better defined. We propose that HPV subtype may have prognostic importance and that the relationship between subtype and clinical behavior warrants further investigation.
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